NCT02785562View on ClinicalTrials.gov

Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression.

NACompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

July 21, 2016

Primary Completion Date

April 6, 2020

Study Completion Date

April 6, 2020

Conditions
Lung Cancer
Interventions
OTHER

Assessment of PDL1 expression

Intervention : 2 biopsy slides will be analyzed in central laboratory.

Trial Locations (13)

13100

Site 12, Aix-en-Provence

24019

Site 19, Périgueux

29200

Centre Hospitalier du Morvan, Brest

49033

Centre Hospitalier Universitaire, Angers

60021

Site 22, Beauvais

63000

Site 48, Clermont-Ferrand

69655

Site 11, Villefranche-sur-Saône

76031

Site 18, Rouen

85000

Centre Hospitalier Les Oudairies, La Roche-sur-Yon

87042

Centre Hospitalier Universitaire DUPUYTREN, Limoges

94010

Site 33, Créteil

95100

Centre Hospitalier D Argenteuil, Argenteuil

05000

Site 04, Gap

All Listed Sponsors
lead

Groupe Francais De Pneumo-Cancerologie

OTHER

NCT02785562 - Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression. | Biotech Hunter | Biotech Hunter